Arnet Isabelle, Gudka Sajni, Salter Sandra, Hersberger Kurt E, Clifford Rhonda
Department of Pharmaceutical Sciences, Pharmaceutical Care Research Group, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.
School of Allied Health, M315 Pharmacy, University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia.
Sex Reprod Healthc. 2018 Jun;16:138-153. doi: 10.1016/j.srhc.2018.03.006. Epub 2018 Mar 29.
To assess chlamydia knowledge, willingness to undertake pharmacy-based chlamydia testing, and facilitators and barriers to such testing in consumers and community pharmacists, in Australia (AUS) and Switzerland (CH).
Statements of interest were retrieved from literature and assembled into a 12-item online survey (English and German versions). Survey was disseminated through Facebook, pharmacies' publicly available emails and professional websites (March 2015).
Consumers and pharmacists (AUS: n = 198, n = 162; CH: n = 209, n = 223) were predominantly female (>65%). Mean chlamydia knowledge scores (maximum of 8) were higher in Australia in consumers (AUS: 6.8 ± 1.5 vs CH: 4.2 ± 2.4; p < 0.001) and in pharmacists (AUS: 7.1 ± 1.1 vs CH: 6.1 ± 1.4; p < 0.001). High willingness of consumers to seek testing (AUS: 79.3% vs CH: 83.3%, p = 0.3) and of pharmacists to provide testing (AUS: 95.7% vs CH: 80.3%, p < 0.001) was observed. Greatest barrier for consumers was "Embarrassed about asking for a test" (AUS: 47.8% vs CH: 51.2%, p = 0.7) and "No remuneration" for pharmacists (AUS: 40.7% vs CH: 31.8%, p = 0.07).
The majority of consumers and pharmacists support pharmacy-based chlamydia testing. There is now emerging evidence that the policy makers in Australia and Switzerland need to develop pharmacy-based chlamydia testing as core business.
评估澳大利亚(AUS)和瑞士(CH)消费者及社区药剂师对衣原体的了解程度、接受基于药房的衣原体检测的意愿,以及此类检测的促进因素和障碍。
从文献中检索感兴趣的陈述,并整理成一份包含12个条目的在线调查问卷(英文和德文版)。该调查于2015年3月通过脸书、药房公开的电子邮件和专业网站进行传播。
消费者和药剂师(澳大利亚:n = 198,n = 162;瑞士:n = 209,n = 223)中女性占主导(>65%)。澳大利亚消费者(澳大利亚:6.8±1.5 vs 瑞士:4.2±2.4;p<0.001)和药剂师(澳大利亚:7.1±1.1 vs 瑞士:6.1±1.4;p<0.001)的衣原体知识平均得分(满分8分)更高。观察到消费者寻求检测的意愿较高(澳大利亚:79.3% vs 瑞士:83.3%,p = 0.3),药剂师提供检测的意愿也较高(澳大利亚:95.7% vs 瑞士:80.3%,p<0.001)。消费者最大的障碍是“对要求检测感到尴尬”(澳大利亚:47.8% vs 瑞士:51.2%,p = 0.7),药剂师的最大障碍是“没有报酬”(澳大利亚:40.7% vs 瑞士:31.8%,p = 0.07)。
大多数消费者和药剂师支持基于药房的衣原体检测。现在有新的证据表明,澳大利亚和瑞士的政策制定者需要将基于药房的衣原体检测发展为核心业务。